IMMUNOME

Protein Array

CodeProduct Name
30008A

Sengenics Immunome Discovery Array

Order on Science Exchange

Product Highlights

Product Description

Contains over 1600 correctly folded and functional human proteins spotted in quadruplicate. Patented KREX functional proteomics technology which utilises the BCCP folding marker for the production of correctly folded and functional proteins. Services include running of samples on the arrays using the Sengenics Standard Lab Protocol. Advanced bioinformatics analysis: Data normalisation, quality control and biomarker panel selection using machine learning.

Specifications

Product Namexx
Product Name

Sengenics Immunome Discovery Array

Platform

Sengenics' proprietary Streptavidin-coated hydrogel surface chemistry provides an aqueous environment, preserving native protein folding and function. Due to the binding of the biotinylated BCCP folding marker with Streptavidin, proteins are oriented consistently with a single attachment point and are also distal (50Å) to the surface further enhancing their capability to fully interact with target biomolecules. KREX proteins behave as if they are in free solution, with full capability to interact at high specificity with autoantibodies and antibodies

Number of samples

1 sample per slide

Services

Services include running of samples on the arrays using the Sengenics Standard Lab Protocol. Advanced bioinformatics analysis: Data normalisation, quality control and biomarker panel selection using machine learning

Sample type

Human serum/plasma
*please contact us for requirements of other types of samples

Delivery Lead Time

6 to 8 weeks

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389

X